Canakinumab
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 76 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Collaborators
- National Cancer Institute (NCI), Novartis
- Tags
- Monoclonal Antibody
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1517
- NCT Identifier
- NCT04239157
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.